Remove Biopharma Remove Leads Remove Pharmaceutical products Remove Sales
article thumbnail

Pfizer secures rights for RSV therapeutic candidate sisunatovir in China

Pharmaceutical Technology

Under the deal terms, LianBio will receive an upfront payment of $20m and is also eligible for up to $135m in potential development and commercial milestones and net sales of sisunatovir in the territories. In 2020, LianBio and Pfizer partnered to develop and commercialise transformative pharmaceutical products in Greater China.